- Home
- PBT vs NEO Comparison
PBT vs NEO Comparison
Compare PBT & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBT | NEO |
|---|---|---|
| Founded | 1980 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Precision Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | PBT | NEO |
|---|---|---|
| Price | $28.19 | $10.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 226.4K | ★ 1.3M |
| Earning Date | 03-13-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | $57.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.80 | $4.72 |
| 52 Week High | $32.25 | $13.74 |
Technical Indicators
Market Signals| Indicator | PBT | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 74.64 |
| Support Level | $17.23 | $9.35 |
| Resistance Level | $32.25 | $10.66 |
| Average True Range (ATR) | 2.26 | 0.45 |
| MACD | -0.11 | 0.18 |
| Stochastic Oscillator | 55.41 | 95.96 |
Price Performance
Historical ComparisonAbout PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.